Page 145 - CW E-Magazine (26-11-2024)

Pharmaceuticals Pharmaceuticals

on sustained release formulations, Dr. Lennon noted that the trend to provide valuable support not just to the HOT MELT EXTRUSION
bioavailability enhancement, and topi- ‘naturals’ is here to stay in the beauty dynamic Indian market, but also to other
cal applications. For personal care, it and personal care industries, and Gatte- affi liates across the globe,” he added. STEERLife and Callidus forge partnership to accelerate
develops cosmetic products and specifi c fossé is well placed to cater to this
formulas for skincare, haircare, suncare need, with its range of sustainably Bullish on India innovative drug development
and colour cosmetics to meet local sourced and produced natural, bio- Later, while speaking at the inaugu-
needs and trends. degradable ingredients with complete ration ceremony, Ms. Moyrand-Gros, STEERLife, a pioneer in pharma- strengths, STEERLife and Callidus Research Laboratories represents a
traceability along the supply, at times pointed out that India, “one of the ceutical development technologies, will provide clients with advanced signifi cant leap forward in pharma-
Expanded manufacturing footprint all the way to the farms in which they world’s most dynamic markets for both and Callidus Research Laboratories, drug development services utilising ceutical innovation,” said Ms. Indu
Gattefossé’s manufacturing foot- were produced. “The challenge for pharmaceuticals and personal care”, is a formulation development services Hot Melt Extrusion (HME) technology. Bhushan, CEO, STEERLife. “This
print earlier spanned France (since ingredient suppliers is to ensure biode- a natural and strategic fi t for Gattefossé. company with a wealth of experience This partnership enables both organi- collaboration empowers clients with
1966) and Singapore (since 2012) but gradability without compromising on in comprehensive pharmaceutical drug sations to integrate their specialised cutting-edge technologies, extensive
has recently expanded with the setting functionality,” she added, noting that “About 30 years ago, we already development, have forged a strategic knowledge and skills, yielding inno- product development expertise, and
up of a large facility in Lufkin City, Gattefossé has, for example, deve- believed that India was a strategic partnership to accelerate drug develop- vative solutions and enhanced product seamless scale-up capabilities.”
Texas (USA) for the manufacture of loped a natural fi lm former, but will not country for Gattefossé group and ment for global markets. offerings. Additionally, the collaboration
lipid-based speciality ingredients for launch it till the functionality is proven. its development. 20 years ago, we facilitates network, contact, and market “Partnering with STEERLife en-
the personal care and pharmaceutical “In the meanwhile, we are advocating realised that establishing an appli- The collaboration combines reach sharing, allowing both companies hances our capabilities, allowing us
industries. The company operates inverse emulsions as fi lm formers for cation laboratory was essential to STEERLife’s advanced Hot Melt to enter new regions and customer seg- to provide comprehensive, innovative
through 12 affi liates, supported by a sunscreens,” she noted. better serve our customers locally, Extrusion (HME) and Continuous ments. Jointly, they will meet the global solutions to pharmaceutical companies
network of 40 distributors, and 78% and we turned that idea into reality,” Processing Technologies with Callidus’ demand for next-generation pharma- worldwide,” said Mr. Vardhaman Bafna,
of its sales now come from outside of With the Indian regulators, like their she said. Pharmaceutical Drug Development ceutical formulations, serving generic Co-founder & Director of Callidus
France. counterparts elsewhere in the world, Expertise, addressing the global demand and brand companies. The partnership Research Laboratories. “This collabora-
demanding substantiation of claims Mr. Jean-Marc Séré-Charlet, the for innovative drug formulations and also enables end-to-end drug develop- tion exemplifi es our dedication to pushing
According to Mr. Eduardo de Purgly, made for personal care ingredients, Consul General of France, remarked development. ment for highly potent APIs. boundaries, fostering growth, and improving
Gattefossé Group CEO, the USA Gattefossé, she is added, is well-placed, as that the Gattefossé group has been patient outcomes through transformative
facility will expand the international it can provide scientifi cally-documented innovating for the last 150 years, and By leveraging their combined “Our partnership with Callidus pharmaceutical solutions.”
reach of Gattefossé, and reduce lead proof of performance. it’s important that the company now BIOSIMILARS
times for deliveries in what is one of the focus on regions with potential for
largest markets in the world. Strong customer support and growth. “Collectively French compa- CuraTeQ Biologics gets GMP certifi cate from EMA
partnerships nies have realised that India is now on
“We recognise that India dominates Speaking at the press conference, the map of global growth,” he empha- Aurobindo Pharma subsidiary, fi lling, packaging and QC testing and Makkapati said in a release on November
the global markets for generic and Dr. Sunil Bambarkar, Gattefossé India sised. CuraTeQ Biologics, has received a release laboratories. 12, 2024. “Our portfolio comprises
super generics, and serves as a major Managing Director, traced the growth GMP certifi cate of compliance for 14 biosimilars in development across
export hub for markets worldwide. It is of the company here from a Liaison In his address, Mr. de Purgly said, its biosimilars manufacturing facility “This inspection outcome paves oncology and immunology segments.
also establishing itself as a key player Offi ce operating from a 100-sq.ft. space, “This is fi fth time we are relocating, from the European Medicines Agency way for securing approvals for three We are dedicated to building a sustain-
in R&D and clinical trials,” he added. to its present well-equipped offi ce in the and each time we move, we expand our (EMA). The GMP inspection, conducted biosimilars in Europe, currently under able biosimilars portfolio and bringing
Godrej Corporate Park. The growth, he resources and facilities to better serve by EMA representatives from April 8-12, review by the Agency, within the next two these essential therapies to patients,”
Strong growth in personal care added, has been made possible by the the Indian market. This expansion is assessed mammalian and microbial to fi ve months,” Aurobindo Pharma’s Vice-Chairman and Managing Director of
markets strong support of discerning customers proof of our commitment to supporting drug substance manufacturing facility Director and CEO of Biologics, Aurobindo Pharma, Mr. K. Nithyananda
Dr. Paula Lennon, Personal Care who perceive value in the offerings of growth and innovation in a country sections, prefi lled syringes and vials Vaccines and Peptides, Mr. Satakarni Reddy said.
Unit Group Director, noted that the Gattefossé India, and the partnerships that holds immense importance to our
Indian personal care market is expected to with academic institutions including business strategy and vision”. US-based AptarGroup begins work on new plaint in Taloja
grow faster than many other territories the Bombay College of Pharmacy and
in Asia, “This is the right time to invest the Institute of Chemical Technology “Since its creation Gattefossé AptarGroup, the US-based drug and metered dose inhaler (pMDI) valve, as inhalers and nasal sprays domestically
in the team in India,” she told Chemical with which Gattefossé India has had India has posted consistent growth every consumer product delivery solutions, well as breath-actuated devices and sin- and for export markets. The new Taloja
Weekly. “We have identifi ed several projects. year, and our investment in the new has broken ground on its new pharma gle-dose nasal sprays. Aptar is a leading plant will also enable Aptar to meet the
domestic brands, including those facility and the state-of-the-art laboratory plant in Taloja, near Mumbai. The new provider of inhalation devices, which region’s growing needs by adding an
catering to the premium segments of the “We are confi dent that Gattefossé is a natural step in Gattefossé’s deve- facility will expand the company’s are critical for delivery of the drugs additional 4,400 square metres of manu-
markets for haircare, skincare, suncare India, with its sustained growth and lopment,” added Mr. Jérôme Delannoy, existing footprint in the region while used to treat respiratory diseases such as facturing footprint and will be con-
and colour cosmetics, and are looking highly skilled team of professional, Group Director International Develop- adding local production of several tech- asthma. The company is helping Indian structed adjacent to the existing Aptar
to develop further business with them.” will continue to expand its reach and ment, Gattefossé. nologies including Aptar’s pressurised pharmaceutical companies in launching Mumbai facility that opened in 2023.

144 Chemical Weekly November 26, 2024 Chemical Weekly November 26, 2024 145

Contents Index to Advertisers Index to Products Advertised